Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
Status:
Unknown status
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial investigating the effectiveness and safety of the study drug RAD001
in patients with advanced (metastatic) cholangiocarcinoma. Palliative chemotherapy provides
some benefit to this group of patients. However, chemotherapy treatment only shows low rates
of radiological response and short times to tumour progression. Therefore, further treatment
options are urgently required.
In laboratory studies, RAD001 has been shown to interrupt the signals that cancer cells use
to grow, spread and form new blood vessels (angiogenesis). RAD001 has been approved for the
treatment of kidney cancer. It has also been approved for use in Australia for the treatment
of patients with kidney and liver transplants, and has been used in thousands of patients
worldwide for this indication. Preliminary studies suggest that RAD001 may have activity in a
range of other cancers. This study will evaluate the activity of RAD001 in advanced
cholangiocarcinoma.